Molecular profiles of small cell lung cancer subtypes : therapeutic implications
(2021) In Molecular Therapy - Oncolytics 20. p.470-483- Abstract
Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers) is an exceptionally lethal malignancy characterized by rapid doubling time and high propensity to metastasize. In contrast to the increasingly personalized therapies in other types of lung cancer, SCLC is still regarded as a homogeneous disease and the prognosis of SCLC patients remains poor. Recently, however, substantial progress has been made in our understanding of SCLC biology. Advances in genomics and development of new preclinical models have facilitated insights into the intratumoral heterogeneity and specific genetic alterations of this disease. This worldwide resurgence of studies on SCLC has ultimately led to the development of novel... (More)
Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers) is an exceptionally lethal malignancy characterized by rapid doubling time and high propensity to metastasize. In contrast to the increasingly personalized therapies in other types of lung cancer, SCLC is still regarded as a homogeneous disease and the prognosis of SCLC patients remains poor. Recently, however, substantial progress has been made in our understanding of SCLC biology. Advances in genomics and development of new preclinical models have facilitated insights into the intratumoral heterogeneity and specific genetic alterations of this disease. This worldwide resurgence of studies on SCLC has ultimately led to the development of novel subtype-specific classifications primarily based on the neuroendocrine features and distinct molecular profiles of SCLC. Importantly, these biologically distinct subtypes might define unique therapeutic vulnerabilities. Herein, we summarize the current knowledge on the molecular profiles of SCLC subtypes with a focus on their potential clinical implications. Small cell lung cancer is still regarded as a homogeneous disease associated with poor prognosis. Recent analysis, however, has led to the development of novel subtype-specific classifications primarily based on the neuroendocrine features and molecular profiles. The better understanding of these biologically distinct subtypes might help to define unique therapeutic vulnerabilities.
(Less)
- author
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- heterogeneity, molecular profile, neuroendocrine, small cell lung cancer
- in
- Molecular Therapy - Oncolytics
- volume
- 20
- pages
- 14 pages
- publisher
- Cell Press
- external identifiers
-
- scopus:85101336149
- pmid:33718595
- ISSN
- 2372-7705
- DOI
- 10.1016/j.omto.2021.02.004
- language
- English
- LU publication?
- yes
- id
- 0bad35ed-fa50-43dd-8cbf-2ac57a91e213
- date added to LUP
- 2021-03-09 09:56:08
- date last changed
- 2024-04-18 03:55:20
@article{0bad35ed-fa50-43dd-8cbf-2ac57a91e213, abstract = {{<p>Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers) is an exceptionally lethal malignancy characterized by rapid doubling time and high propensity to metastasize. In contrast to the increasingly personalized therapies in other types of lung cancer, SCLC is still regarded as a homogeneous disease and the prognosis of SCLC patients remains poor. Recently, however, substantial progress has been made in our understanding of SCLC biology. Advances in genomics and development of new preclinical models have facilitated insights into the intratumoral heterogeneity and specific genetic alterations of this disease. This worldwide resurgence of studies on SCLC has ultimately led to the development of novel subtype-specific classifications primarily based on the neuroendocrine features and distinct molecular profiles of SCLC. Importantly, these biologically distinct subtypes might define unique therapeutic vulnerabilities. Herein, we summarize the current knowledge on the molecular profiles of SCLC subtypes with a focus on their potential clinical implications. Small cell lung cancer is still regarded as a homogeneous disease associated with poor prognosis. Recent analysis, however, has led to the development of novel subtype-specific classifications primarily based on the neuroendocrine features and molecular profiles. The better understanding of these biologically distinct subtypes might help to define unique therapeutic vulnerabilities.</p>}}, author = {{Schwendenwein, Anna and Megyesfalvi, Zsolt and Barany, Nandor and Valko, Zsuzsanna and Bugyik, Edina and Lang, Christian and Ferencz, Bence and Paku, Sandor and Lantos, Andras and Fillinger, Janos and Rezeli, Melinda and Marko-Varga, Gyorgy and Bogos, Krisztina and Galffy, Gabriella and Renyi-Vamos, Ferenc and Hoda, Mir Alireza and Klepetko, Walter and Hoetzenecker, Konrad and Laszlo, Viktoria and Dome, Balazs}}, issn = {{2372-7705}}, keywords = {{heterogeneity; molecular profile; neuroendocrine; small cell lung cancer}}, language = {{eng}}, pages = {{470--483}}, publisher = {{Cell Press}}, series = {{Molecular Therapy - Oncolytics}}, title = {{Molecular profiles of small cell lung cancer subtypes : therapeutic implications}}, url = {{http://dx.doi.org/10.1016/j.omto.2021.02.004}}, doi = {{10.1016/j.omto.2021.02.004}}, volume = {{20}}, year = {{2021}}, }